EGFR and non-small cell lung carcinoma: A few studies have identified the potential mechanisms for GE primary or acquired resistance in NSCLC, including KRAS mutations as well as mutations on EGFR kinase activity sites, ultimately inducing gain of function of such an oncogene, in which the transformation of T790M and C797S in EGFR are the top two forms (8).